Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health
Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.
You may also be interested in...
Valeant Returns $1bn Female Libido Drug For Free
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.
Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.
FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs
Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.